* U.S. UNIT SUBMITTED NDA TO FDA ON SEPT. 28, TO SEEK
MARKETING APPROVAL FOR RBP-7000, INDIVIOR’S TREATMENT OF
SCHIZOPHRENIA​
Source text for Eikon:
Further company coverage:

Read More At Article Source | Article Attribution